National Pension Service Has $57.14 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

National Pension Service raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 107.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,170,640 shares of the company’s stock after purchasing an additional 1,640,940 shares during the period. National Pension Service’s holdings in Teva Pharmaceutical Industries were worth $57,135,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. QRG Capital Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after buying an additional 50,247 shares during the last quarter. Capital Wealth Planning LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $2,169,000. SG Americas Securities LLC grew its holdings in shares of Teva Pharmaceutical Industries by 12.0% during the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after purchasing an additional 65,529 shares during the last quarter. Coronation Fund Managers Ltd. acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $1,334,000. Finally, Point72 Asset Management L.P. lifted its stake in Teva Pharmaceutical Industries by 38.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock valued at $21,437,000 after purchasing an additional 363,217 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays upped their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, July 10th. Finally, UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $18.78 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a 52 week low of $8.55 and a 52 week high of $19.08. The firm has a 50 day moving average of $18.03 and a 200-day moving average of $17.06. The company has a market cap of $21.27 billion, a price-to-earnings ratio of -48.14, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.